Arbutus Biopharma Corporation (Nasdaq: ABUS) recently presented compelling data on its investigational hepatitis B therapies, ...

Viral hepatitis is a leading cause of liver disease, liver cancer and liver transplant in the United States and is a focus of an annual national awareness campaign that occurs ...

Vir Biotechnology’s sidelined hepatitis B candidate, designed to serve as a “functional cure,” has failed to achieve the ...

Vir Bio (VIR) reveals 24-week post-end-of-treatment data from a mid-stage trial for its Hep B therapy developed with Xencor ...

Hepatitis is an inflammation of the liver, most commonly caused by a viral infection. The three main types—Hepatitis A, B, ...

The Knox County Health Department shared in a press release that each May, the United States observes Hepatitis Awareness Month to bring attention to viral hepatitis and ...

Ongoing clinical studies for four candidates on track with data expected in 2025, including interim Phase 1b data for long-acting helicase-primase inhibitors ABI-5366 and ABI-1179 anticipated in fall ...

Discover a recent study presented at EASL 2025 that explored the impact of opt-out testing for blood-borne viruses in ...

Title: ALG-055009, a potent and selective thyroid hormone receptor beta agonist for the treatment of metabolic ...

Discover an awarding winning abstract from EASL 2025 that has called for more person-centred hepatitis screening. Learn more.

Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the first quarter ended March 31, 2025.